JP2019527053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527053A5 JP2019527053A5 JP2019500261A JP2019500261A JP2019527053A5 JP 2019527053 A5 JP2019527053 A5 JP 2019527053A5 JP 2019500261 A JP2019500261 A JP 2019500261A JP 2019500261 A JP2019500261 A JP 2019500261A JP 2019527053 A5 JP2019527053 A5 JP 2019527053A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- sfgfr3
- growth factor
- fibroblast growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022046573A JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359607P | 2016-07-07 | 2016-07-07 | |
| US62/359,607 | 2016-07-07 | ||
| US201762467478P | 2017-03-06 | 2017-03-06 | |
| US62/467,478 | 2017-03-06 | ||
| PCT/EP2017/067119 WO2018007597A1 (en) | 2016-07-07 | 2017-07-07 | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046573A Division JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527053A JP2019527053A (ja) | 2019-09-26 |
| JP2019527053A5 true JP2019527053A5 (https=) | 2020-08-20 |
| JP7046903B2 JP7046903B2 (ja) | 2022-04-04 |
Family
ID=59381265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500261A Expired - Fee Related JP7046903B2 (ja) | 2016-07-07 | 2017-07-07 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
| JP2022046573A Active JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046573A Active JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294289B2 (https=) |
| EP (2) | EP3481859B1 (https=) |
| JP (2) | JP7046903B2 (https=) |
| KR (2) | KR20220122762A (https=) |
| CN (1) | CN109715658B (https=) |
| AU (2) | AU2017294551B2 (https=) |
| BR (1) | BR112019000257A2 (https=) |
| CA (1) | CA3029877C (https=) |
| DK (1) | DK3481859T3 (https=) |
| ES (1) | ES2912559T3 (https=) |
| HU (1) | HUE058734T2 (https=) |
| IL (1) | IL264030A (https=) |
| MX (1) | MX2018016257A (https=) |
| PL (1) | PL3481859T3 (https=) |
| PT (1) | PT3481859T (https=) |
| RU (1) | RU2751483C2 (https=) |
| SG (1) | SG11201900074WA (https=) |
| SI (1) | SI3481859T1 (https=) |
| WO (1) | WO2018007597A1 (https=) |
| ZA (1) | ZA201900507B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| JP7335247B2 (ja) * | 2017-09-20 | 2023-08-29 | ファイザー・インク | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
| WO2020243478A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Eye And Ear Infirmary | Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss |
| US11625937B2 (en) * | 2020-04-06 | 2023-04-11 | Toyota Motor Engineering & Manufacturing North America, Inc. | Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN116284327A (zh) * | 2023-03-28 | 2023-06-23 | 中国药科大学 | 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| WO1996041620A1 (en) | 1995-06-12 | 1996-12-27 | Yeda Research And Development Co., Ltd. | Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| AU2002235202A1 (en) | 2000-12-18 | 2002-07-01 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP2003104908A (ja) | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ES2374822T3 (es) | 2004-02-24 | 2012-02-22 | Allergan, Inc. | Ensayo de selección de toxinas botul�?nicas. |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| EP2083846B1 (en) | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| EP2318529B1 (en) * | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| MA33208B1 (fr) | 2009-03-25 | 2012-04-02 | Genentech Inc | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| RU2012134637A (ru) | 2010-01-14 | 2014-02-20 | Йейл Юниверсити | Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| JP6162707B2 (ja) | 2011-10-24 | 2017-07-12 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法 |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| WO2014018673A2 (en) | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| US20140030259A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| PE20170256A1 (es) | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| EP3242888B8 (en) | 2015-01-07 | 2021-06-02 | Pfizer Inc. | Soluble fgfr3 decoys for treating skeletal growth disorders |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| JP7335247B2 (ja) | 2017-09-20 | 2023-08-29 | ファイザー・インク | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
-
2017
- 2017-07-07 MX MX2018016257A patent/MX2018016257A/es unknown
- 2017-07-07 WO PCT/EP2017/067119 patent/WO2018007597A1/en not_active Ceased
- 2017-07-07 AU AU2017294551A patent/AU2017294551B2/en not_active Ceased
- 2017-07-07 CN CN201780049433.8A patent/CN109715658B/zh not_active Expired - Fee Related
- 2017-07-07 BR BR112019000257A patent/BR112019000257A2/pt not_active IP Right Cessation
- 2017-07-07 ES ES17742195T patent/ES2912559T3/es active Active
- 2017-07-07 HU HUE17742195A patent/HUE058734T2/hu unknown
- 2017-07-07 EP EP17742195.5A patent/EP3481859B1/en active Active
- 2017-07-07 KR KR1020227027503A patent/KR20220122762A/ko not_active Ceased
- 2017-07-07 PL PL17742195T patent/PL3481859T3/pl unknown
- 2017-07-07 PT PT177421955T patent/PT3481859T/pt unknown
- 2017-07-07 JP JP2019500261A patent/JP7046903B2/ja not_active Expired - Fee Related
- 2017-07-07 SG SG11201900074WA patent/SG11201900074WA/en unknown
- 2017-07-07 CA CA3029877A patent/CA3029877C/en active Active
- 2017-07-07 DK DK17742195.5T patent/DK3481859T3/da active
- 2017-07-07 EP EP22167483.1A patent/EP4122955A1/en not_active Withdrawn
- 2017-07-07 SI SI201731158T patent/SI3481859T1/sl unknown
- 2017-07-07 KR KR1020197002602A patent/KR102432192B1/ko active Active
- 2017-07-07 RU RU2019100381A patent/RU2751483C2/ru active
-
2018
- 2018-04-02 US US15/943,436 patent/US10294289B2/en active Active
- 2018-12-30 IL IL264030A patent/IL264030A/en unknown
-
2019
- 2019-01-24 ZA ZA2019/00507A patent/ZA201900507B/en unknown
- 2019-05-20 US US16/417,174 patent/US11021528B2/en not_active Expired - Fee Related
-
2021
- 2021-04-20 US US17/234,841 patent/US11697678B2/en active Active
-
2022
- 2022-03-23 JP JP2022046573A patent/JP7348980B2/ja active Active
- 2022-05-02 AU AU2022202906A patent/AU2022202906A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527053A5 (https=) | ||
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| RU2019100381A (ru) | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения | |
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| ES2389697T3 (es) | Variantes de desintegrina y usos farmacéuticos de los mismos | |
| JP2017529059A5 (https=) | ||
| CN102643339B (zh) | 一种glp-1类似物、制备方法及其应用 | |
| JP7672122B2 (ja) | 生物活性複合体の調製 | |
| JP2016518351A5 (https=) | ||
| CN112521514A (zh) | 一种蛋白复合物及其制备方法和应用 | |
| PT92278B (pt) | Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina | |
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| EP4389216A2 (en) | Peptide compositions and therapeutic uses | |
| AU2015356997A1 (en) | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases | |
| US20200062811A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| CN103732240B (zh) | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 | |
| HUP0104126A2 (hu) | Gyógyszer a csontmetabolizmus hibáira | |
| CA3133830A1 (en) | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins | |
| CN101208106A (zh) | 癌症治疗剂 | |
| KR102745928B1 (ko) | 혈액뇌장벽을 통과 가능한 폴리펩티드 | |
| JP3059283B2 (ja) | 抗炎症剤 | |
| CA3220239A1 (en) | A super-trail molecule comprising two trail trimers | |
| CN113355308A (zh) | 用于中和冠状病毒的人工多肽、制备方法及药物组合物 | |
| AU2005328131A1 (en) | Anticancer agent | |
| JPH07503705A (ja) | 医薬的リジン含有ポリペプチド組成物およびその使用法 |